Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

Shelley Wood

December 29, 2016

News Daily News

Engrosamiento de las Valvas y Durabilidad de la Válvula Post-TAVR con Balón Autoexpandible: Nuevos Datos de Estudios

Todd Neale

December 26, 2016

News Conference News

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Todd Neale

November 04, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

Presenter: Krzysztof Bartus, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

TCT 26: Long-term Event Rates for Left Atrial Appendage Closure With WATCHMAN: PROTECT AF Five-Year and PREVAIL Three-Year Follow-up

Presenter: Zahid Amin, Jacqueline Saw, Vivek Y. Reddy

October 31, 2016

Presentation TCT 2016

TransMitral Valve Replacement (VIV) Within a St. Jude Mechanical Mitral Valve

Presenter: Danny Dvir, Marco Moscarelli, J. Bradley Oldemeyer

October 31, 2016

Presentation TCT 2016

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Jamil Abdalla Saad

October 30, 2016

Presentation TCT 2016

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Josep Rodés-Cabau

October 30, 2016

Presentation TCT 2016

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Yat-Yin Lam

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Horst Sievert

October 30, 2016

Presentation TCT 2016

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Apostolos Tzikas

October 30, 2016

Presentation TCT 2016

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Presenter: A. Pieter Kappetein, Allan Schwartz, Danny Dvir

October 30, 2016

Presentation TCT 2016

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, David R. Holmes Jr.

October 30, 2016

Presentation TCT 2016

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Presenter: Vivek Y. Reddy, Steven J. Yakubov

October 30, 2016

Presentation TCT 2016

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Matthew J. Price

October 30, 2016

Presentation TCT 2016

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Marc Gillinov

October 30, 2016

Presentation TCT 2016

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Presenter: Karl-Heinz Kuck, DJ Lakkireddy, Freek W.A. Verheugt, Vivek Y. Reddy

October 30, 2016

Advertisement

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Las Noticias y Blogs Más Populares de TCTMD en 2016

Engrosamiento de las Valvas y Durabilidad de la Válvula Post-TAVR con Balón Autoexpandible: Nuevos Datos de Estudios

Watchman, Amulet LAA Closure Devices Carry Low Complication Rates

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

TCT 26: Long-term Event Rates for Left Atrial Appendage Closure With WATCHMAN: PROTECT AF Five-Year and PREVAIL Three-Year Follow-up

TransMitral Valve Replacement (VIV) Within a St. Jude Mechanical Mitral Valve

Rationale for and Outcomes of LAA Closure Plus Pulmonary Vein Isolation

Early Clinical Results With the Cardia LAA Occluder (and Future Studies)

Early and Late Results With the LAmbre LAA Occluder (and Future Studies)

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Early and Late Results With the Occlutech LAA Occluder (and Future studies)

Synthesis of ACP/Amulet Studies in Anticoagulated Indicated and Contra-indicated Patients: Certainties, Data Gaps, and Future Studies

Bioprosthetic Valve Failure: TAVR Clinical and Hemodynamic Results From the VIVID Registry and Other Studies

Use of Watchman in Anticoagulant Contraindicated Patients: Has Safety and Efficacy Been Proven?

Meta-analysis and Synthesis of Watchman Trials: Relative Safety and Efficacy vs Warfarin and NOACs in Anticoagulant Indicated Patients (Including Cost-effectiveness)

Epicardial Closure of the LAA With the Lariat: What Do we Know About Its Safety and Efficacy?

Surgical Approaches to LAA Closure: Techniques, Devices, and Results

Outcomes and Role of Ablation in the Treatment Approach to Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content